Sundance Pharmaceuticals is applying for emergency use authorizations to launch clinical trials to treat acute respiratory distress syndrome in COVID-19 hospitalized patients and for a nasal spray to reduce the risk of and length of illness in COVID-19 infections.

The trials are expected to begin July of 2020. Initial trials will be in locations of high risk and minority populations in the U.S. and Canada.